SYNTEX/GENEMEDICINE $20 MIL. GENE THERAPY COLLABORATION
Executive Summary
SYNTEX/GENEMEDICINE $20 MIL. GENE THERAPY COLLABORATION to develop non-viral gene medicines for treating rheumatoid arthritis, osteoarthritis and asthma and preventing organ transplant rejection is announced by the companies April 13. As part of the agreement, GeneMedicine has obtained a co-exclusive worldwide license and the right to sublicense Syntex' DOTMA cationic lipid technology that provides for the delivery of gene therapeutics. GeneMedicine brings to the venture "controlled, cell-specific gene expression and non-viral delivery systems" in inflammation and immunology, the companies said.